Showing 1 - 10 of 578
Generic pharmaceuticals provide low-cost access to treatment. Despite their chemical equivalence to branded products …
Persistent link: https://www.econbiz.de/10012949948
Economic literature has extensively studied how prices for incumbent pharmaceutical drugs respond to generic competition after entry. However, less attention has been paid to pricing behavior in anticipation of brand-to-brand competition. We contribute to this gap in the literature by both...
Persistent link: https://www.econbiz.de/10012925274
We examine the issue of new goods and price indexes for the important and tractable case of generic and branded drugs. By treating generics as entirely distinct goods and "linking them in" to indexes with fixed weights, the standard price indexes fail to reflect the substantial welfare gains to...
Persistent link: https://www.econbiz.de/10013243636
I use variation in approval time for generic drugs to shed light on the objectives of the federal agency in charge of granting entry permission for these drugs (FDA). Applications belonging to firms later found to have engaged in fraud or corruption were approved nine months faster on average,...
Persistent link: https://www.econbiz.de/10013324056
In this paper I use data on all generic drug approvals granted from 1984- 1994 to examine whether heterogeneity among potential generic entrants can be used to predict which firms will choose to enter a particular market. The findings suggest that a firmamp;apos;s portfolio characteristics,...
Persistent link: https://www.econbiz.de/10012774927
We examine six molecules facing initial loss of US exclusivity (LOE, from patent expiration or challenges) between June 2009 and May 2013 that were among the 50 most prescribed molecules in May 2013. We examine prices per day of therapy (from the perspective of average revenue received by retail...
Persistent link: https://www.econbiz.de/10013062618
We study the effects of generic entry on prices and utilization using both event study models that exploit the differential timing of generic entry across drug molecules and cast studies. Our analysis examines drugs treating hypertension, high blood pressure, type 2 diabetes, and depression...
Persistent link: https://www.econbiz.de/10013093453
During the 1980s the share of prescriptions sold by retail pharmacies that was accounted for by generic products roughly doubled. The price response to generic entry of brand-name products has been a source of controversy. In this paper we estimate models of price responses to generic entry in...
Persistent link: https://www.econbiz.de/10014158702
There is a long-standing literature that recognizes that an efficient solution in correcting a consumption externality is through applying subsidies and taxes that line up private incentives with social ones. An equally long-standing literature tackles the appropriate methods of generating the...
Persistent link: https://www.econbiz.de/10013237532
relative magnitudes of the two sources of competition in limiting innovative returns in the U.S. pharmaceuticals market. In …
Persistent link: https://www.econbiz.de/10013225118